University of California, Irvine

Venture capital fundraising by biopharmaceutical companies has been a mixed bag so far in 2023, with a slow start to the year but a relative surge in big financings in March and April. There were only

Scrip regularly reviews technology transfer activity across the biopharmaceutical sector. Recent editions of Tech Transfer Roundup focused on oncology and COVID-19 deals. This reviews the rest of

Once a poster child for high-cost cancer drugs, Roche 's VEGF inhibitor Avastin is now being heralded as more cost effective as an add-on maintenance treatment in advanced ovarian cancer than PARP

Below is Scrip’s monthly roundup, including information from Strategic Transactions , of recent technology transfer agreements between companies and academic or other research institutions. Amgen, M